A Phase 3 placebo-controlled clinical trial which assessed the efficacy of lorcaserin, a novel selective agonist of the serotonin 2C receptor, in reducing the weight in obese patients.

Analysis showed that 47% of lorcaserin patients lost at least 5% of their body weight, compared to 25% of placebo patients. Lorcaserin patients lost an average of 6%/6 kg, compared to 3%/3 kg for those taking a placebo. 

Abbreviation Behavioral modification and LOrcaserin Second Study for Obesity Management

References J Clin Endocrinol Metab. 2011 Oct;96(10):3067-77.
doi: 10.1210/jc.2011-1256

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.